Keytruda plus chemotherapy is now a first-line treatment for pleural mesothelioma, replacing chemotherapy alone as the standard of care. The KEYNOTE-483 trial showed significant improvements in ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

RAHWAY, N.J.& KINGSTON, Ontario---- Merck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group today announced that the Phase 2/ 3 CCTG IND.227/KEYNOTE-483 ...

In many other countries, the rate of mesothelioma is still increasing.” 3. References. 1. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line ...

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

Malignant Pleural Mesothelioma (MPM): KEYTRUDA as a first-line treatment may be combined with chemotherapy medicines to treat MPM, a cancer that affects the lining of the lungs and chest wall.

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

Pleural mesothelioma, which develops in the lining of the lungs, is the most common form of the disease, accounting for about 75% of all cases. “Malignant pleural mesothelioma is a rapidly progressing ...

Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) ...